凯信远达上涨5.67%，报2.05美元/股，总市值3176.00万美元

Core Insights - CASI Pharmaceuticals (凯信远达) experienced a stock price increase of 5.67% on August 16, reaching $2.05 per share, with a total market capitalization of $31.76 million [1] - For the fiscal year ending March 31, 2025, CASI reported total revenue of $6.24 million, reflecting a year-over-year growth of 83.04%, while the net profit attributable to shareholders was a loss of $10.75 million, a decrease of 12.83% compared to the previous year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focused on providing advanced treatment solutions for blood cancers in Chinese patients [2] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi, China [2] - CASI's product and research pipeline addresses multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2]